BIRC5 and breast carcinoma: Thus, the in vivo efficacy of recombinant survivin as a cancer vaccine was tested along with the adjuvants alum and Mw in the breast cancer model 4T1, which expresses high levels of survivin compared to normal breast tissue (149).